A Philadelphia judge said that a punitive damages award of $6 million in a hormone-replacement therapy case was supported by drugmaker Wyeth’s public relations campaign to ‘"dismiss and distract physicians’" from the increased risk of breast cancer allegedly posed by HRT drugs.
Philadelphia Common Pleas Court Judge Mark I. Bernstein, the presiding judge in Singleton v. Wyeth , wrote in his June 30 opinion that the jury verdict affirmed that the plaintiffs proved that Wyeth, now owned by Pfizer, negligently provided inadequate warnings about the risk of breast cancer from taking Prempro, that Wyeth did not conduct the appropriate breast cancer studies and that Wyeth actively tried to ensure that breast cancer data remained cloaked from health care providers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
